Trials / Completed
CompletedNCT00336557
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
A Randomized, Controlled, Open-Label Parallel Group Study to Evaluate the Effect of Regularly Scheduled Neutralizing Antibody Testing on Treatment Patterns Versus Usual Care in High-Dose Interferon Treated Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,230 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
Detailed description
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | NAbs testing | blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test. |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2009-04-01
- Completion
- 2009-07-01
- First posted
- 2006-06-13
- Last updated
- 2013-10-30
Locations
49 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00336557. Inclusion in this directory is not an endorsement.